Porta, C. (2010). Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’. Nature Publishing Group.
Citação norma ChicagoPorta, C. Regarding: ‘Costs of Managing Adverse Events in the Treatment of First-line Metastatic Renal Cell Carcinoma: Bevacizumab in Combination With Interferon-α2a Compared With Sunitinib’. Nature Publishing Group, 2010.
Citação norma MLAPorta, C. Regarding: ‘Costs of Managing Adverse Events in the Treatment of First-line Metastatic Renal Cell Carcinoma: Bevacizumab in Combination With Interferon-α2a Compared With Sunitinib’. Nature Publishing Group, 2010.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.